[go: up one dir, main page]

LV12210B - The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy - Google Patents

The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy Download PDF

Info

Publication number
LV12210B
LV12210B LVP-98-237A LV980237A LV12210B LV 12210 B LV12210 B LV 12210B LV 980237 A LV980237 A LV 980237A LV 12210 B LV12210 B LV 12210B
Authority
LV
Latvia
Prior art keywords
salt
pharmaceutically acceptable
pharmaceutical composition
formula
composition according
Prior art date
Application number
LVP-98-237A
Other languages
English (en)
Latvian (lv)
Other versions
LV12210A (lv
Inventor
Raymond Baker
Kendal G. Pitt
Victor G. Matassa
David E. Storey
Carole Olive
Leslie J. Street
Alexander Richard Guiblin
Original Assignee
Merck Sharp & Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211903A external-priority patent/GB9211903D0/en
Priority claimed from GB939307306A external-priority patent/GB9307306D0/en
Application filed by Merck Sharp & Dohme Ltd filed Critical Merck Sharp & Dohme Ltd
Publication of LV12210A publication Critical patent/LV12210A/xx
Publication of LV12210B publication Critical patent/LV12210B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
LVP-98-237A 1992-06-05 1998-10-26 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy LV12210B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211903A GB9211903D0 (en) 1992-06-05 1992-06-05 Pharmaceutical composition
GB939307306A GB9307306D0 (en) 1993-04-07 1993-04-07 Therapeutic agents

Publications (2)

Publication Number Publication Date
LV12210A LV12210A (lv) 1999-01-20
LV12210B true LV12210B (en) 1999-03-20

Family

ID=26301005

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-237A LV12210B (en) 1992-06-05 1998-10-26 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Country Status (27)

Country Link
US (1) US5527817A (fi)
EP (1) EP0573221B1 (fi)
JP (2) JP2619197B2 (fi)
KR (1) KR100286411B1 (fi)
CN (1) CN1043532C (fi)
AT (1) ATE165602T1 (fi)
AU (2) AU4337293A (fi)
BG (1) BG61976B1 (fi)
CA (1) CA2097208C (fi)
CZ (1) CZ282060B6 (fi)
DE (1) DE69318212T2 (fi)
DK (1) DK0573221T3 (fi)
ES (1) ES2116411T3 (fi)
FI (3) FI106201B (fi)
HK (1) HK1010050A1 (fi)
HU (1) HUT71403A (fi)
IL (1) IL105847A (fi)
LV (1) LV12210B (fi)
MX (1) MX9303373A (fi)
NO (1) NO307420B1 (fi)
NZ (1) NZ253210A (fi)
RO (1) RO114326B1 (fi)
RU (1) RU2130022C1 (fi)
SG (1) SG50406A1 (fi)
SK (1) SK279211B6 (fi)
UA (1) UA27908C2 (fi)
WO (1) WO1993025547A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
CA2225416C (en) * 1995-07-11 2009-02-24 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
WO2007054979A1 (en) * 2005-11-14 2007-05-18 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
US12194158B2 (en) 2016-01-27 2025-01-14 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2024144413A1 (ru) * 2022-12-28 2024-07-04 Общество С Ограниченной Ответственностью "Ферринг Продакшн" Жидкая фармацевтическая композиция для назального введения, содержащая ризатриптан

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528319A3 (ru) * 1985-07-23 1989-12-07 Глэксо Груп Лимитед (Фирма) Способ получени производных имидазола или их физиологически приемлемых солей
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
EP0407137B1 (en) * 1989-07-03 1996-05-01 Yoshitomi Pharmaceutical Industries, Ltd. Benzazine compounds and pharmaceutical uses thereof
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CZ282060B6 (cs) * 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby

Also Published As

Publication number Publication date
BG61976B1 (bg) 1998-11-30
AU3987593A (en) 1993-12-09
JP2972150B2 (ja) 1999-11-08
FI945694A0 (fi) 1994-12-02
FI20001777A7 (fi) 2000-08-10
JP2619197B2 (ja) 1997-06-11
IL105847A (en) 1998-09-24
JPH09176155A (ja) 1997-07-08
UA27908C2 (uk) 2000-10-16
DE69318212T2 (de) 1998-11-19
DE69318212D1 (de) 1998-06-04
FI106201B (fi) 2000-12-15
EP0573221B1 (en) 1998-04-29
ES2116411T3 (es) 1998-07-16
ATE165602T1 (de) 1998-05-15
KR100286411B1 (ko) 2001-04-16
FI20001776L (fi) 2000-08-10
RU2130022C1 (ru) 1999-05-10
DK0573221T3 (da) 1998-10-07
LV12210A (lv) 1999-01-20
NO944656D0 (no) 1994-12-02
EP0573221A1 (en) 1993-12-08
BG99132A (bg) 1995-07-28
NZ253210A (en) 1995-09-26
JPH0641121A (ja) 1994-02-15
CA2097208C (en) 2005-02-08
HUT71403A (en) 1995-11-28
CN1089263A (zh) 1994-07-13
FI945694L (fi) 1994-12-02
FI20001776A7 (fi) 2000-08-10
CZ304494A3 (en) 1995-09-13
CN1043532C (zh) 1999-06-02
HU9403478D0 (en) 1995-02-28
HK1010050A1 (en) 1999-06-11
IL105847A0 (en) 1993-09-22
WO1993025547A1 (en) 1993-12-23
CZ282060B6 (cs) 1997-05-14
AU659311B2 (en) 1995-05-11
FI20001777L (fi) 2000-08-10
US5527817A (en) 1996-06-18
AU4337293A (en) 1994-01-04
KR950701922A (ko) 1995-05-17
NO944656L (no) 1994-12-02
SK279211B6 (sk) 1998-08-05
SG50406A1 (en) 1998-07-20
SK147994A3 (en) 1995-07-11
RU94046380A (ru) 1996-12-10
MX9303373A (es) 1995-01-31
CA2097208A1 (en) 1993-12-06
RO114326B1 (ro) 1999-03-30
NO307420B1 (no) 2000-04-03

Similar Documents

Publication Publication Date Title
EP0490689B1 (en) 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate (2:1)
US5527817A (en) Sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
HK1010050B (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
CA2225416C (en) A triazolylmethyl-indole ethylamine bisulfate salt
HRP940225A2 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy